|Mr. Spiro George Rombotis||Chief Exec. Officer, Pres and Exec. Director||745.02k||N/A||57|
|Mr. Paul McBarron||Chief Financial Officer, Chief Operating Officer, Exec. VP of Fin., Sec. and Exec. Director||453.28k||N/A||55|
|Dr. Judy H. Chiao M.D.||VP Clinical Devel. and Regulatory Affairs||464.16k||N/A||56|
|Prof. David Glover Ph.D., FRS FRSE||Chief Scientist||N/A||N/A||68|
|Dr. Susan Davis Ph.D.||Director of Bus. Devel.||N/A||N/A||N/A|
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs for the treatment of cancer and other diseases. The companys oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; in Phase II clinical trial for myelodysplastic syndromes; and in Phase I/II clinical trial in combination with seliciclib, a drug candidate to treat solid tumors. Its oncology development programs also comprise Seliciclib, an oral inhibitor of cyclin dependent kinase (CDK) 2/9 enzymes, which are central to the process of cell division and cell cycle control that has completed a Phase IIb clinical trial; and CYC065, a second generation CDK inhibitor, which is in Phase I clinical trial targeting CDK2/9 enzymes with potential utility in hematological malignancies and solid tumors. In addition, the companys oncology development programs include CYC140, a polo-like kinase inhibitor program that is in preclinical development stage; and Aurora Kinase inhibitors, a serine/threonine protein kinases that focuses on cell division or mitosis for the treatment of cancer. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.
Cyclacel Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.